SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Retz, Margitta; Bedke, Jens; Bögemann, Martin; Grimm, Marc-Oliver; Zimmermann, Uwe; Müller, Lothar; Leiber, Christian; Teber, Dogu; Wirth, Manfred; Bolenz, Christian; van Alphen, Robbert; De Santis, Maria; Beeker, Aart; Lehmann, Jan; Indorf, Martin; Frank, Melanie; Bokemeyer, Carsten; Gschwend, Jürgen E.

期刊名称European Journal of Cancer
作者Retz, Margitta; Bedke, Jens; Bögemann, Martin; Grimm, Marc-Oliver; Zimmermann, Uwe; Müller, Lothar; Leiber, Christian; Teber, Dogu; Wirth, Manfred; Bolenz, Christian; van Alphen, Robbert; De Santis, Maria; Beeker, Aart; Lehmann, Jan; Indorf, Martin; Frank, Melanie; Bokemeyer, Carsten; Gschwend, Jürgen E.
卷第107卷
印刷ISSN0959-8049
文件大小744.66KB
发表时间2019-01
DOI10.1016/j.ejca.2018.11.001
页码37-45

发现好书期刊，享受阅读乐趣

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)